INTRODUCTION
Whilst life-saving secondary prevention interventions exist for people diagnosed 1 valve surgery) 23, 24, 32 , whereas others included CHD patients with or without 1 intervention. Four studies had an upper age limit, meaning that elderly patients were 2 excluded from the sample. 32, 34, 35, 37 Two studies were based on data from the multi-3 country European Action on Secondary Prevention through Intervention to Reduce 4 Events (EUROASPIRE) survey, but there was no overlap in the study populations since 5 these articles were from separate waves of the survey. 35, 37 In most cases, study 6 populations were recruited from hospitals or patient databases, with one exception 7 which included a population sample. 30 8
Smoking prevalence at baseline 9
Amongst the eight studies which recruited both smokers and non-smokers with 10 CHD, 23, 24, 27, 29, 30, 32, 34, 35 the average smoking prevalence at baseline was 51% (SD ±15). 11
Prevalence of smoking at baseline by gender is shown in Table 2 . Females with CHD 12 were significantly less likely to be smokers than males in six of the eight studies. The 13 average rate of smoking at baseline in females was 31% (SD ±14) compared to 57% (SD 14 ±18) in males (p<0.0001). Subsequently, meta-analysis of all eight studies revealed that 15 females had a 70% lower odds of being smokers at baseline than males (OR 0.30, 95% 16 CI 0.13 to 0.70). The direction of effect did not differ when sensitivity analyses were 17 smoking/relapse was significantly higher in females in two studies, 23, 25 but was similar 1 between genders in all other studies. There was no gender difference in the rate of 2 persistent smoking/relapse in the meta-analysis of all sixteen included studies (OR 1.07, 3 95% CI 0.95 to 1.21) and this result was consistent when sensitivity analyses were 4 conducted excluding each study in turn and also when we considered the overall odds 5 ratio in the fixed effects model (Figure 3) . 6
Smoking status at follow-up was invariably based on patients' self-reporting, but 7 follow-up periods within which persistent smoking behaviour or relapse was assessed 8 varied considerably between studies (Table 1) . Length of follow-up was summarised 9 into five categories which showed that: three studies followed patients up to 3 10 months 29, 31, 32 ; two up to six months 22, 26 ; four up to 12 months 25, 27, 33, 36 ; six followed 11 patients for 1-3 years 23, 24, 30, 34, 35, 37 ; and, one study followed patients for up to 13 years. 28 12
Relapse rates were lower in the studies which followed-up only until 3 months and 13 higher in studies which followed-up until 12 months, but length of follow-up did not 14 affect the direction of effect when sensitivity analyses were conducted. The rate of 15 relapse was similar in males and females even when the results were analysed by sub-16 group classified on length of follow-up category. 17
Quality level of the selected studies 18
Grading was undertaken independently by two authors. The GRADE approach was 19 designed to be used in evaluating clinical trials/interventions being systematically 20 reviewed and, therefore, observational studies have a default rating of "low." 38 Although 21 upgrading and downgrading of studies can occur in some circumstances, all of the 22 observational studies in this current review remained in the low quality category. 39 The 23 two randomized controlled trials included in the review were also rated "low", because 24 they did not provide the number of persistent/ relapsed smokers by gender; they 1 provided odds ratios which we were able to include in the meta-analysis. 2 3
DISCUSSION

4
The key finding of this systematic review and meta-analyses was that, although female 5 smokers formed only a small minority of the CHD population, those still smoking at the 6 time of diagnosis or hospitalisation were just as likely as male smokers to persist in 7 smoking or relapse following hospital discharge. 8
The finding that just over half of the aggregated study population were smokers, 9 whilst considerably higher than smoking prevalence in the general population where 10 each of the studies originated, 9 is comparable to other studies of patients with CHD. 11
Although the number of smokers worldwide continues to increase due to population 12 growth, the prevalence of smoking has declined over the last twenty-five years so that 13 6% of females and 31% of males worldwide are currently estimated to smoke. 40 14 However, population smoking prevalence varies considerably around the world from 15 <5% to >40% in some countries. 9 Smoking prevalence also varies by age group, tending 16 to be higher amongst young people and decline with age; for example in Australia 8% of 17 females and 12% of males in the 65-74 age group smoke, compared with national 18 averages of 14% and 18% respectively. 41 Despite this pattern, amongst people 19 diagnosed or hospitalised for CHD -who are typically aged over 50 -smoking 20 prevalence tends to be higher because of the role of smoking in the development of 21 atherosclerosis leading to CHD. 42-44 22 In our study we found a gender difference in the prevalence of smoking, whereby 23 females with CHD were significantly less likely than males to be smokers at the time of 24 diagnosis or hospitalisation, which is consistent with patterns of smoking prevalence by 25 gender in the global population as well as those found in many other CHD studies. 40,41,45-1 47 There is a possibility that, because female smokers form such a minority of the CHD 2 population, delivery of smoking cessation advice and intervention for females could be 3 overlooked. This is a concern because, as foreshadowed, the risks from smoking are 4 even greater for females than males and the dangers of relapse post-diagnosis or 5 hospitalisation for CHD are significant in terms of subsequent mortality and morbidity 6 in both genders. 8,19,25,36,42 7 In this meta-analysis, the rate of persistent smoking or relapse post-diagnosis or 8 hospitalisation was similar amongst females and males. This is contrary to our 9 hypothesis which suggested that females might find it more difficult to quit smoking 10 than males and, therefore, be more vulnerable to relapse. However, a non-significant 11 relationship between relapse and gender has been noted in several other CHD 12 studies. 14,47-51 Recent population cohort studies and meta-analyses of non-CHD 13 populations have also found that females were neither less likely to quit smoking nor 14 less successful in their quit attempts than males. 20,52 Whilst gender does not, therefore, 15 appear to be a predictor for relapse, factors which have been found to be associated 16 with failed quit attempts or resumption post-discharge include: low-confidence in 17 quitting; fewer prior attempts to quit; low household income; having other smokers in 18 the household; high nicotine dependence; low self-efficacy; severity of withdrawal 19 symptoms; lower education level; ethnicity; behavioural and psychosocial 20 factors. 14, 16, 19, [53] [54] [55] People who are depressed or suffer from anxiety or psychiatric 21 disorders are known to be particularly vulnerable to relapse. 14,50 Women have been 22
shown to find smoking cessation more difficult at certain stages of the menstrual cycle; 23 but in light of the older age of onset of CHD in women, 6 it is unlikely to be a factor in 24 smoking relapse amongst this generally post-menopausal cohort. 25
The relationships between clinical factors such as type of CHD diagnosis, disease 1 severity, extent of coronary intervention and rate of relapse are interesting, though not 2 fully understood. Whilst those relationships were outside the specific aims of this 3 systematic review, we found that the study in which all patients underwent CABG had 4 the highest cessation rate. 32 A recent randomised controlled trial with 5-year follow up 5
reported that coronary revascularization reduced the number of smokers by half, which 6 led the investigators to think about the effectiveness of smoking cessation advice at the 7 time of revascularization. 56 Whilst others have also found high rates of abstinence for 8 CABG patients compared to those admitted for MI, 43 one study noted that previous 9 CABG appeared to be a paradoxically positive predictor of relapse. 50 Perez et al. 50 10 hypothesised that undergoing CABG might lead patients to mistakenly think their 11 disease was cured and be more complacent about smoking cessation. Another study 12
found that higher cessation rates in CABG patients one month post-procedure were no 13 longer apparent at 12 months, which caused the investigators to wonder whether 14 longer hospitalisation due to CABG was an influencing factor for short-term 15 abstinence. 57 It is interesting to note that the two studies included in our review in 16 which the rate of relapse was significantly higher in females than males were those 17 which only included patients who had received PCI with stent or underwent cardiac 18 surgery, 23,24 although rates of relapse did not differ significantly by gender in the study 19 limited to CABG patients. 32 Blum et al. 23 interpreted the lower rate of cessation in 20 females as a weakness of the intervention, suggesting that in future it should be better 21 targeted towards females. 22
Hospitalisation with ACS has been identified as a teachable moment for smoking 23 cessation, but nevertheless -as confirmed in this review -rates of relapse are often 24 high. 57 Patients may feel greater motivation to quit following a health scare and use the 25 period of enforced abstinence in hospital to kick-start their cessation attempt. 14,58 1 However, the duration of hospitalisation for MI can be quite short and lack of time may 2 impede the delivery of smoking cessation support. 5 A longer stay in hospital or longer 3 recovery period (for example related to more severe, multi-vessel or major artery 4 disease, coronary interventions or CABG) has been shown to positively influence 5 smoking cessation, possibly because it gives clinicians more time to try to motivate 6 patients and their relatives to quit smoking. 28,32,49,57 7 Half of the patients in our study were able to quit smoking spontaneously but the 8 other half (47%) continued to smoke post-diagnosis or hospitalisation. This is 9 consistent with other studies which have noted 30%-60% smoking relapse rates in CHD 10 populations. 14, 49, 50 In our review, although rates of persistent smoking/relapse were 11 lower in studies which had relatively short (3 months) follow-up periods, length of 12 follow-up did not affect the direction of the effect in meta-analysis of relapse by gender, 13 which was consistently similar in females and males. The weeks immediately following 14 hospital discharge are often when patients are most susceptible to relapse, as they settle 15 back into their normal routine and life-style. 25, 53 The follow-up periods in the included 16 studies varied from three months to thirteen years, and we note that both studies which 17 found a higher rate of relapse amongst females than males had relatively long follow-up 18 periods (>1 year). 23, 24 In relation to the length of follow-up, in their systematic review 19 and meta-analysis of relapse after one year of abstinence, Hughes et al. 59 concluded that 20 a non-significant amount of relapse occurs after a year but did not report on this by 21 gender. 22
High rates of persistent smoking/relapse post-diagnosis or hospitalisation for 23 CHD highlight the importance of interventions which support patients and improve 24 smoking cessation. Although, as we have shown, the rate of persistent smoking/relapseis similar in females and males, gender differences in the experience of smoking and 1 relapse remain important issues for an effective intervention design. For example, it has 2 been demonstrated that females attempting to quit experience a higher impact of 3 depression, more severe withdrawal symptoms, more fear of weight gain and have a 4 greater reliance on social supports than males, prompting the World Health 5
Organization Framework Convention on Tobacco Control to recommend a gendered 6 perspective in prevention programs. 17 However, evidence to date indicates that, 7 although female specific programs do help women to stop smoking, such programs 8 produce similar abstinence rates to non-gender-specific programs. 15 Attendance at 9 cardiac rehabilitation has been shown to be effective in improving smoking cessation, 10 nevertheless substantial proportion of attendees are known to relapse within a few 11 weeks. 25, 53 Evidence also suggests that intensive, sustained interventions, involving 12 behavioural modification counselling along with pharmacotherapy, nursing 13 interventions and interventions addressing tempting situations, are the most 14 effective. [60] [61] [62] [63] Multifactorial lifestyle interventions to improve modifiable risk factors, 15 including smoking cessation, diet and physical activity, have also been shown to reduce 16 mortality and morbidity in CHD patients. 64 Few studies in in our review involved a 17 specific smoking intervention, but amongst those that did, three noted improved 18 smoking cessation in the intervention group, 22, 23, 26 whilst the fourth found no additional 19 benefit of bupropion over and above intensive nurse counselling. 33 Many tools to assist 20 in smoking cessation support have been validated for use by health care professionals, 21 including motivational interviewing and use of the 5 A's (Ask, Advise, Assess, Assist,Arrange) when addressing patient's tobacco use. 17 Motivational interviewing has been 23 shown to improve rates of smoking cessation and nurse-led motivational interviewing 24 has been used successfully in patients. 65 The delivery of smoking cessation advice forpatients post ACS is also recognised as being the responsibility of physicians in general 1 practices. 66 In light of the fact that smoking cessation is so important, and because 2 admission to hospital provides patients with an impetus to quit smoking, more 3 consistent and sustained interventions are required in order to capitalise on this 4 opportunity to provide cessation support to both female and male smokers. 62,63,67 5
Limitations 6 There was some heterogeneity between studies in terms of sample populations, follow-7 up and interventions. However, we addressed this by using the random effects model 8 and conducting sensitivity analyses to ensure that variances in study design did not 9 change our overall findings. Since smoking prevalence was not the main objective of the 10 review, we included a number of studies where all participants were smokers and 11
baseline. This means that our prevalence of 7% female smokers in the aggregated 12 sample is likely to be an overestimate. We addressed this issue by analysing prevalence 13 in females vs. males in the eight studies which also included non-smokers. 14 15 CONCLUSION populations. However, the rate of persistent smoking/relapse was high in both female 18 and male smokers following a diagnosis or hospitalisation for CHD. Therefore, similar, 19 sustained smoking cessation efforts are warranted for both genders. 
